Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

v3.5.0.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2016
Notes to Financial Statements  
Note 18 - SUBSEQUENT EVENTS

Effective July 5, 2016, the Company amended its articles of incorporation to increase the authorized shares of capital stock of the Company from two hundred million (200,000,000) shares of common stock and eighty thousand (80,000) shares of preferred stock, both $.001 par value respectively, to five hundred twenty five million (525,000,000) shares common stock, and six hundred thousand (600,000) shares of preferred stock, both $.001 par value respectively.

  

In July 2016, the Company issued 700,000 shares of its common stock for consulting services.

 

Effective July 28, 2016, the Company entered into a Development, Commercialization and License Agreement with TheraKine Ltd. The Company was granted an exclusive worldwide license to utilize the Technology in developing injectable naltrexone products to treat patients suffering from addiction to opioids, methamphetamines, cocaine, or alcohol.